Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK7 | P50613 | 19/20 | 1.00 |
| ▸ | CCNH | P51946 | 19/20 | 1.00 |
| ▸ | CCNK | O75909 | 18/20 | 1.00 |
| ▸ | CDK12 | Q9NYV4 | 17/20 | 1.00 |
| ▸ | CDK9 | P50750 | 16/20 | 1.00 |
| ▸ | CCNT1 | O60563 | 15/20 | 1.00 |
| ▸ | CDK13 | Q14004 | 14/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 14/20 | 1.00 |
| ▸ | CDK2 | P24941 | 14/20 | 1.00 |
| ▸ | MNAT1 | P51948 | 11/20 | 1.00 |
| ▸ | CDK3 | Q00526 | 1/20 | 1.00 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16664894 | 1.00 | CDK7 (1.00) | CDK7CCNHCCNKCDK12CDK9 | |
| SCHEMBL29392974 | 1.00 | CDK7 (1.00) | CDK7CCNHCCNKCDK12CDK9 | |
| SCHEMBL16655251 | 1.00 | CDK7 (1.00) | CDK7CCNHCCNKCDK12CDK9 | |
| SCHEMBL16655250 | 1.00 | CDK7 (1.00) | CDK7CCNHCCNKCDK12CDK9 | |
| SCHEMBL29434977 | 1.00 | CDK7 (1.00) | CDK7CCNHCCNKCDK12CDK9 | |
| SCHEMBL16655252 | 1.00 | CDK7 (1.00) | CDK7CCNHCCNKCDK12CDK9 | |
| SCHEMBL16655070 | 0.97 | CCNK (1.00) | CDK7CCNHCCNKCDK12CDK9 | |
| SCHEMBL16655118 | 0.97 | CCNK (1.00) | CDK7CCNHCCNKCDK12CDK9 | |
| SCHEMBL16655115 | 0.97 | CCNK (1.00) | CDK7CCNHCCNKCDK12CDK9 | |
| SCHEMBL16655072 | 0.97 | CCNK (1.00) | CDK7CCNHCCNKCDK12CDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240101707-A1 | A METHOD OF PREVENTING, ALLEVIATING OR TREATING A TUMOR | JIANGSU ALPHAMAB BIOPHARMACEUTICALS CO., LTD. (CN) | 2024-03-28 | — | — | US | disclosed |
| US-11789025-B2 | Reagents and methods for analysis of proteins and metabolites targeted by covalent probes | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-02-16 | — | — | US | disclosed |
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-08-05 | — | — | US | disclosed |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-07-29 | — | — | US | disclosed |
| US-11040957-B2 | Heteroaromatic compounds useful for the treatment of proliferative diseases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-11040957-B2 | Heteroaromatic compounds useful for the treatment of proliferative diseases | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-06-22 | — | — | US | disclosed |
| US-20190015411-A9 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-01-17 | — | — | US | disclosed |
| US-20180169097-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-06-21 | — | — | US | disclosed |
| EP-3057955-B1 | HETEROAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLFERATIVE DISEASES | SYROS PHARMACEUTICALS INC (US) | 2018-04-11 | — | — | EP | disclosed |
| EP-3057955-B1 | HETEROAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLFERATIVE DISEASES | SYROS PHARMACEUTICALS INC (US) | 2018-04-11 | — | — | EP | disclosed |
| WO-2016201370-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-12-15 | — | — | WO | disclosed |
| US-20160264551-A1 | HETEROAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLFERATIVE DISEASES | SYROS PHARMACEUTICALS, INC. (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160264551-A1 | HETEROAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLFERATIVE DISEASES | SYROS PHARMACEUTICALS, INC. (US) | 2016-09-15 | — | — | US | disclosed |
| EP-3057955-A1 | HETEROAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Syros Pharmaceuticals, Inc. (US) | 2016-08-24 | — | — | EP | disclosed |
| WO-2015058126-A1 | HETEROAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLFERATIVE DISEASES | SYROS PHARMACEUTICALS, INC. (US) | 2015-04-23 | — | — | WO | disclosed |
| WO-2015058126-A1 | HETEROAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLFERATIVE DISEASES | SYROS PHARMACEUTICALS, INC. (US) | 2015-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ATXN2L, ATXN2, ATXN10 | CDK7 1492/4885CCNH 989/4885CCNK 1807/4885 |
| US-11040957-B2 | Heteroaromatic compounds useful for the treatment of proliferative diseases | CDK7, CDK3, CDK4 | CDK7 1/4885CCNH 29/4885CCNK 8/4885 |
| US-20180169097-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | CHUK, BCOR, MYC | CDK7 130/4885CCNH 539/4885CCNK 140/4885 |
| US-20160264551-A1 | HETEROAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLFERATIVE DISEASES | CDK7, CDK6, CDK3 | CDK7 1/4885CCNH 30/4885CCNK 12/4885 |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | CDK7 2782/4885CCNH 2396/4885CCNK 2881/4885 |
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | CDK7 2782/4885CCNH 2396/4885CCNK 2881/4885 |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | CYFIP2, TPX2, ATXN2 | CDK7 2892/4885CCNH 3635/4885CCNK 4146/4885 |
| US-11789025-B2 | Reagents and methods for analysis of proteins and metabolites targeted by covalent probes | PTMS, SRMS, HSP90B1 | CDK7 2189/4885CCNH 2179/4885CCNK 2169/4885 |
| US-20190015411-A9 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | CHUK, BCOR, MYC | CDK7 130/4885CCNH 539/4885CCNK 140/4885 |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ZFX, F13B, GRN | CDK7 2487/4885CCNH 2294/4885CCNK 3185/4885 |
| US-20240101707-A1 | A METHOD OF PREVENTING, ALLEVIATING OR TREATING A TUMOR | CDK2, CDK12, CDK1 | CDK7 45/4885CCNH 56/4885CCNK 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.